Description overdue on 09/24/2013

NSAIDs . The principle of operation is based on the UPSA Upsarin indiscriminate lowering activity of cyclooxygenase 1 and 2, are actively involved in the synthesis of prostaglandins (formed pain and swelling in the area of ​​inflammation). The drug has analgesic, anti-inflammatory, moderate, antipyretic effects. The active substance is acetylsalicylic acid . By reducing the concentration of prostaglandins in thermoregulation decreases body temperature by sweating and expansion of the lumen of blood vessels. Analgesic effect It reached central and peripheral actions of acetylsalicylic acid. The drug inhibits the synthesis of thromboxane A2 in cells of the platelet reducing thrombus formation, adhesion and aggregation of platelets. After a single dose of Uppsala made UPSARIN antiplatelet effect   It can be stored for seven days (the severity of this effect is stronger in males compared to females).

The drug reduces the risk of myocardial infarction and mortality rate in the diagnosis of unstable angina form. Effectively used in susceptible individuals for the primary and secondary prevention of myocardial infarction. At a dose of 6 grams per day increases the rate of prothrombin time and simultaneously inhibits the formation of prothrombin in the hepatic system. Upsarin UPSA is able to reduce the level of vitamin K-dependent clotting factors (2, 7, 9, 10), the figure increases fibrinolytic activity of plasma. The treatment medication significantly increases the risk of bleeding and hemorrhagic complications   during surgical interventions. Due to violations of the reabsorption of uric acid in renal tubules of acetylsalicylic acid stimulates the excretion. The drug reduces the activity of gastroprotective (protective) prostaglandins, blocking cyclooxygenase-1, which may give rise to ulceration of the stomach wall, followed by bleeding. Preference is given to recommended dosage forms which contain a special enteric coating, buffer substances. Issue additional forms of medication - Upsarin UPSA with vitamin C. It is a complex preparation that contains ascorbic and acetylsalicylic acid. Vitamin C has been actively involved with the oxidation and reduction processes, controls blood clotting The process for synthesizing various compounds and carbohydrate metabolism. Ascorbic acid has a strong antioxidant effect   and increases the regenerative potential of tissues.

Indications:

The drug is prescribed for pain syndrome : Neuralgia, headache, myalgia, lumbago , Toothache, tuberculosis, arthralgia, radicular syndrome. The drug Upsarin UPSA is used for the relief of moderate febrile syndrome That accompanies many diseases infectious-inflammatory. In unstable angina, the form, the form of silent myocardial ischemia, myocardial infarction, in the diagnosis of multiple risk factors for coronary heart disease after Prosthetic heart valves After coronary balloon angioplasty, after installation of the specific stent with aortoarteriit When coronary artery neateroskleroticheskogo origin, with mitral valve prolapse , Dressler's syndrome, acute thrombophlebitis, pulmonary infarction Upsarin UPSA prescribed as an antiplatelet agent in a daily dose of 300 mg.

Contraindications:

Different hemorrhagic diathesis (thrombocytopenic purpura, hemophilia, hypoprothrombinemia, telangiectasia, von Willebrand's disease), the presence of "Aspirin triad"   (simultaneous diagnosis of relapsing forms of nasal polyposis and adjacent sinuses, asthma and intolerance to drugs pirazolonovogo series, acetylsalicylic acid). The drug is not indicated in patients with erosive and ulcerative diseases of the mucous wall of the digestive tract (acute stage, exacerbation), intolerance to the active ingredient, vitamin K deficiency, pregnancy, severe liver disease and renal system. Application Upsarin UPSA breastfeeding is contraindicated. In ulcerative lesions of the digestive system in history, with the form of decompensated heart failure, gout , Hyperuricemia, nefrourolitiaze (urate form) Upsarin UPSA used with caution (requires additional consultation of specialists), evaluating the risks and long-term consequences.

Side effect:

As a result the haptenated mechanism formed "Aspirin asthma"   and "aspirin triad" (includes simultaneous combination of nasal polyposis, adjacent sinuses, asthma and intolerance to drugs pirazolonovogo series and acetylsalicylic acid). Perhaps the development of allergic responses in the form of bronchospasm, various rashes on the skin, angioedema. The drug may cause disorders in the hepatic and renal system. Long-term therapy causes vomiting, dizziness, hypocoagulation, interstitial nephritis , Bronchospasm, erosive and ulcerative lesions of the digestive system (stomach, duodenum), tinnitus, disorders of visual and auditory perception, papillary necrosis , Pre-renal azotemia with hypercalcemia and elevated levels of creatinine, increased severity of clinical symptoms of heart failure, aseptic meningitis, nephrotic syndrome, edema.

Overdose:

Manifested center hyperventilation , Bleeding, anuria, respiratory alkalosis, collapse, drowsiness, metabolic acidosis   and confusion. At the initial stage hyperventilation leads to respiratory alkalosis: cyanosis of the limbs and body, suffocation , Shortness of breath, the appearance of a cold, clammy sweat. Further, as a result of the intoxication develops respiratory paralysis and complete isolation in oxidative phosphorylation, which ultimately leads to respiratory acidosis. If poisoning is recommended provocation of vomiting, laxatives appointment, enterosorbents, activated carbon. Required control parameters electrolyte balance . If necessary, the solution is introduced lactate, citrate or sodium hydrogen carbonate. Increase excretion of acetylsalicylic acid is possible by increasing the reserve alkalinity. For alkalinization of urine is not recommended to use acetazolamide (development acidemia, increased toxic effects of acetylsalicylic acid). In the elderly, intensive fluid therapy may lead to pulmonary edema That must be considered in the treatment of intoxication UPSARIN UPSA. Hemodialysis level of medication prescribed for more than 100-130 mg%. With the development of pulmonary edema designate of mechanical ventilation with a special mixture rich in oxygen.

Mode of application:

Treatment of acute rheumatic fever:   daily dose is calculated by circuit 100 mg per 1 kg of body weight per day, dosing frequency is 5-6 times per day. Pain and feverish syndrome:   500-100 mg per day, divided into three doses. The course of treatment no more than two weeks. How to take Upsarin UPSA: effervescent tablets is recommended to take after a meal, pre-dissolved in water (100-200ml), 3-4 times a day. Duration of treatment may vary from one day to several months. Admission 150-250 mg of aspirin per day can improve the rheological properties of blood. Patients with myocardial infarction, as well as for secondary prevention   it is recommended to take daily 40-325 mg (mean dose of 160 mg). For the inhibition of platelet aggregation cell appoint 300-325 mg of the drug daily. Dosing at Upsarin UPSA cerebral tromboemboliah When dynamic changes in cerebral blood flow: initial dose - 325 mg per day, more gradual increase in the recommended amounts of medication to 1000 mg per day. Acceptance of 125-300 mg per day provides a relapse prevention. Admission atsetilsalitslovoy acid 325 mg every seven hours via a special gastric tube (set intranasally) provides for prevention of aortic graft occlusion and thrombosis. It is further recommended to switch to oral medicament forms: three times a day in a dose of 325 mg in combination therapy with dipyridamole for a week.

Special instructions:

Long-term treatment with Upsarin UPSA require mandatory controls on basic indicators for the state of the blood, regular fecal occult blood. When using the drug as an analgesic acetylsalicylic acid can be taken no more than a week. To achieve the antipyretic effect of the drug can be used no longer than three days. It is recommended that a complete rejection of salicylates up to 7 days before the planned surgery. Application UPSARIN UPSA in pediatric viral diseases at contraindicated because of the risk of   Reye's syndrome (enlargement of the liver, the formation of an acute encephalopathy, uncontrollable vomiting). Careful grinding tablets medications after a meal, the use of enteric form of acetylsalicylic acid, the use of drugs that neutralize the acidity of gastric juice can reduce the irritant effect of the drug Upsarin UPSA mucous wall of the digestive tract. The drug can trigger in predisposed individuals a new gout attack. This impact is explained by a decrease in the amount of output Uric acid   in the treatment of medicament. Aspirin is excreted in breast milk, increasing the risk of bleeding in infants due to functional changes in the platelet blood cells. Use of the drug Upsarin UPSA during pregnancy leads to the formation of malformations (splitting of the upper sky) in the first trimester, and reduces the rate of labor in the third trimester due to inhibition of prostaglandin synthesis. Teratogenic effect   hypertension medication appears in the "small" circle of blood vessels of the lung tissue hyperplasia, premature closure of the ductus arteriosus lumen.

Drug Interactions:

Upsarin UPSA increases the concentration of salts of lithium, barbiturates and Digoxin in blood plasma. Ethanol-containing medicines, glucocorticosteroids Ethanol reinforce the effect of acetylsalicylic acid irritates the mucous wall of the digestive tract (significantly increases the likelihood of gastrointestinal bleeding). Medicament improves reserpine, nonsteroidal antiinflammatory drugs, thrombolytics, indirect anticoagulants , Sulfonamides (such as co-trimoxazole), narcotic analgesics, inhibitors of platelet aggregation cells hypoglycemic agents   (oral forms). The drug enhances the toxic effect Methotrexate . Drug Usage Upsarin UPSA is not recommended for the medication simultaneously with diuretics (veroshpiron, furosemide), hypotensive, uricosuric agents (sulfinpyrazone, benzbromarone). The speed and quality of absorption of acetylsalicylic acid reduced when taking antacids Whose composition went magnesium salts, aluminum. Alcohol and Upsarin UPSA pharmacologically compatible (requires a complete rejection of receiving alcoholic beverages).